Cardiology
SGLT2 Inhibitors, Finerenone and Semaglutide Differ
A meta-analysis of 10 randomized datasets and 37,923 participants found distinct cardiorenal outcome patterns across SGLT2 inhibitors, finerenone and semaglutide, arguing against treating them as interchangeable.
Rayan Salih · October 6, 2026 · 7 min